Citations

Mayo Clinic

Showing 10 of 108599 citations.

CC‐99282 plus R‐CHOP in patients (pts) with previously untreated aggressive B‐cell lymphoma (a‐BCL): early safety and efficacy results from a phase 1b study
Vassilakopoulos, T. P., García‐Sancho, A. M., Rueda‐Domínguez, Antonio , Kwiatek, M., Bouzani, Maria, Gkasiamis, Argyrios, Patel, Amar , Boucaud, Floriane, Nowakowski, Grzegorz S. , Muñoz, Javier , Hoffmann, Marc Steven , Westin, Jason R. , García‐Sancho, A. M., Jurczak, Wojciech , Li, J.

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 584-586

10.1002/hon.3164_438 Get It

Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) and treatment‐naïve (TN) mantle cell lymphoma (MCL)
Melani, Christopher , Phelan, J. D., Yang, Y. , Davies‐Hill, Theresa, Simard, Jillian , Huang, Dawei , Thomas, C. , Tosto, Frances A., Juanitez, Anna Marie, Jacob, Allison P. , Simmons, H., Steinberg, Seth M. , Staudt, Louis M. , Wilson, Wyndham H. , Lakhotia, Rahul , Pittaluga, Stefania , Muppidi, Jagan , Thomas, C. J., Ceribelli, Michele , Pradhan, A., Rimsza, Lisa M. , Jaffe, Elaine S. , Roschewski, Mark

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 582-584

10.1002/hon.3164_437 Get It

Phase 1 trial of EO2463 peptide‐based immunotherapy as monotherapy and in combination with lenalidomide and rituximab in indolent non‐Hodgkin lymphoma; EONHL1‐20/SIDNEY
Pinto, A. A., Bisneto, J. C. Villasboas, Sanz, R. García, García, Carlos Grande, Smith, Stephen D. , Wallace, D. S., Merryman, R., Marolleau, Jean Pierre, Chêne, Laurent , Fagerberg, Jan, Friedberg, Jonathan W. , Ansel, Sonam , Armand, Philippe , Pinto, A., Bosch, Francesc , Bisneto, J. C. Villasboas, Sanz, R. García, Arcaini, Luca , Marolleau, Jean‐Pierre, Filippi, Rosaria De , Bonny, Christophe , Ansel, S., Zinzani, Pier Luigi

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 581-582

10.1002/hon.3164_435 Get It

Multicohort Study of Conditional Survival and Cause of Death After Achieving Event‐Free Survival at 24 Months (EFS24) in Patients With Mantle Cell Lymphoma (MCL)
Wang, Y., Ekberg, Sara , Smedby, Karin E. , Zhao, Ergang, Nowakowski, G. S., Albertsson‐Lindblad, Alexandra , Wang, Yucai , Larson, Melissa C. , Gerrie, Alina S. , Farooq, Umar , Maurer, Matthew J. , Paludo, Jonas , Habermann, Thomas M. , Glimelius, Ingrid , Link, Brian K. , Diego, V., Jerkeman, Mats , Cerhan, James R.

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 472-474

10.1002/hon.3164_347 Get It

Ibrutinib (Ibr) dose modification for management of early cardiac adverse events in patients with chronic lymphocytic leukemia: Pooled analysis of 7 clinical trials
Tedeschi, Alessandra , Ahn, Inhye E. , Fraser, Graeme , Greil, Richard , Saifan, Chadi , Kearbey, Jeffrey D., Patel, Sandipkumar , Munir, Talha , Kay, Neil E. , Flinn, Ian W. , Lee, Shane , Barrientos, Jacqueline C.

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 461-463

10.1002/hon.3164_340 Get It

Comparison of clinical outcomes in patients with relapsed/refractory large B‐cell lymphoma treated with epcoritamab versus chemoimmunotherapy
Mutebi, Alex , Wang, T., Ma, Jun , Wang, A., Yu, Jinhua , Brodkin, Samantha, Kalsekar, Anupama, Ip, Andrew , Rosenthal, Allison , Wang, Trent , Yu, J., Sacchi, M., Muñoz, Javier

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 433-434

10.1002/hon.3164_319 Get It

Defining Primary Refractory Diffuse Large B‐cell Lymphoma (DLBCL) Based on Survival Outcomes
Bock, Allison M. , Mwangi, Raphael , Wang, Y., Khurana, Arushi , Ayers, Amy , Martin, Peter , Cohen, Jonathon B. , Lossos, Izidore S. , Reicks, Tanner W., Flowers, Christopher R. , Nowakowski, Grzegorz S. , Wang, Yucai , Maurer, Matthew J. , Kahl, Brad S. , Casulo, Carla , Farooq, Umar , Ayyappan, Sabarish Ram , Habermann, Thomas M. , Cerhan, James R. , Nastoupil, Loretta J.

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 430-432

10.1002/hon.3164_317 Get It

Depth of metabolic response at interim PET and survival outcomes among patients with primary refractory or early relapsing diffuse large B‐cell lymphoma (DLBCL)
Bock, Allison M. , Mwangi, Raphael , Shreve, J. T., Khurana, Arushi , Wang, Y., Nowakowski, Grzegorz S. , Young, Joseph , Ataei, F., Thorpe, Matthew , Pritchett, Joshua C. , Maurer, Matthew J. , Paludo, Jonas , Cerhan, James R. , Witzig, Thomas E. , Habermann, Thomas M. , Young, J. R.

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 344-345

10.1002/hon.3164_246 Get It

Automated FDG PET/CT radiomics for risk stratification in newly diagnosed diffuse large B‐cell lymphoma (DLBCL)
Shreve, Jacob , Bock, Allison M. , Shah, M. V., Wang, Y., Nowakowski, Grzegorz S. , Novak, Anne J. , Young, Jason R., Ansell, Stephen M. , Hazim, Antonious , Pritchett, Joshua C. , Maurer, Matthew J. , Binder, Moritz , Witzig, Thomas E. , Cerhan, James R. , Habermann, Thomas M. , Paludo, Jonas

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 341-342

10.1002/hon.3164_244 Get It